Abstract 1230P
Background
Lung cancer is the most prevalent and deadliest cancer worldwide, mainly due to its advanced stage at diagnosis. Minimally invasive method for early detection of lung cancer is an urgent need to improve patients’ survival. hPG80 (circulating progastrin) has been previously described as a promising multi-tumors blood biomarker (You et al. EbioMedicine, 2020). hPG80 is produced and released from cancer cells and can be detected in the blood at early steps of tumorigenesis. In this study, we assess the diagnostic value and potential clinical utility of hPG80 in patients with non-small cell lung cancers (NSCLC), including early-stage tumors.
Methods
Plasma hPG80 levels were measured using the kit DxPG80.Lab (Biodena care, Montpellier, France) from two cohorts: (1) a retrospective cohort of 400 NSCLC patients comprising 100 samples per disease stage (I-IV) collected at diagnosis, before any treatment (Nice Hospital-Integrated Biobank BB-0033-00025); (2) a prospective matching age cohort of 330 healthy subjects. The diagnostic value of hPG80 was assessed by comparing hPG80 baseline concentrations in NSCLC patients with those of healthy subjects. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic accuracy of hPG80 using the area under the curve (AUC).
Results
Overall, hPG80 median concentration in all NSCLC patients was significantly higher than in healthy subjects (6.51 pM vs 1.95 pM, P<0.0001). hPG80 median concentrations were significantly higher in all disease stage subgroups than those in healthy subjects (6.83 pM, 7.15 pM, 6.02 pM and 6.34 pM for stage I to stage IV, respectively) (P<0.0001). ROC curve analysis of the entire NSCLC cohort showed that the AUC value was 0.84 (95% CI: 0.81 to 0.87). Following subgroup analysis by disease stages I-IV, the AUC values were 0.86 (95% CI: 0.83 to 0.90), 0.85 (95% CI: 0.81 to 0.88), 0.82 (95% CI: 0.78 to 0.86) and 0.84 (95% CI: 0.80 to 0.87), respectively.
Conclusions
These findings uncover the potency of hPG80 as a novel promising, accurate and non-invasive biomarker to diagnose NSCLC patients, notably at an early stage. Furthermore, its measurement by an ELISA assay may facilitate its routine use for cancer screening/early diagnosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Biodena Care.
Funding
Biodena Care.
Disclosure
A. Prieur, N. Mimoun: Financial Interests, Personal, Member of Board of Directors: Biodena Care. B. Vire: Financial Interests, Personal, Full or part-time Employment: Biodena Care. D. Joubert: Financial Interests, Personal, Advisory Board: Biodena Care. All other authors have declared no conflicts of interest.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1204TiP - Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Presenter: Neel Belani
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14